辛伐他汀对原发性高胆固醇血症患者hs-CRP、vWF的影响

目的探讨辛伐他汀对原发性高胆固醇血症（HC）患者高敏C反应蛋白（hs-CRP）、血管假性血友病因子（vWF）的影响。方法选择HC患者48例,每晚口服辛伐他汀20 mg,分别于治疗前、治疗后4、8周进行hs-CRP、vWF、血脂等指标的测定;另选20例健康体检者对照。结果辛伐他汀治疗前后HC患者血清总胆固醇（TC）、甘油三酯（TG）及低密度脂蛋白胆固醇（LDL-C）含量显著下降（P〈0.05）,高密度胆固醇（HDL-C）含量升高（P〈0.05）。HC患者血清、hs-CRP、血浆vWF含量较正常对照组显著升高（P〈0.05）。辛伐他汀治疗4周后,hs-CRP显著降低（P〈0.05）;治疗8周后,vWF显著降低（P〈0.05）。结论HC患者存在动脉粥样硬化发生发展的基础,辛伐他汀不但能有效调节血脂,而且能抑制炎症反应,修复血管内皮,从而稳定病情发展。

The Effects of Simvastatin on High Sensitivity C-reactive Protein and Von Willebrand Factor in Patients with Primary Hypercholesterolemia

Objective To investigate the effects of simvastatin on high sensitivity C-reaction protein(hs-CRP) and von Willebrand Factor(vWF) in the patients with primary hypercholesterolemia.Methods 48 patients with primary hypercholesterolemia received simvastatin(20 mg QN).Hs-CRP、vWF、lipidemia were mersured at beginning and after 4、8 weeks treatment.Compared with those in 20 heathy subjects.Results Before treatment the level of hs-CRP and vWF were significantly higher than that of healthy subjects(P<0.05).TC、TG、LDL and hs-CRP were decreased significantly after 4 week of simvastatin treatment(P<0.05).The level of HDL was also increased(P>0.05).The level of vWF was decreasd significantly after 8 weeks of treatment(P<0.05).Conclusion There are the foundation of atherosclerosis in patients with hyperlipidemia.Simvastatin treatment not only decreaes the levels of lipidemia,but also lower inflammatory reaction and improve effectively endothelial function.